NOVO NORDISK A/S
Bagsværd, Denmark, 17 November 2014 - Today, it was announced that Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. Novo Nordisk's ranking is a reflection of the company's inclusion of access to medicine within its core business, including equitable pricing strategies, local capability building and integrating philanthropy with business activities.
In 2013, Novo provided medical treatments for approximately 24.3 million people with diabetes worldwide, showing a 7% increase compared with 2012.
"Today, more than 80% of people with diabetes live in low- and middle-income countries where access to medicine and treatment is simply not adequate for the millions in need," says Lars Rebien Sørensen, chief executive officer at Novo Nordisk. "Last year, we launched our Strategy for Global Access to Diabetes Care strengthening our already existing efforts to break down barriers that inhibit access to care and help us reach 40 million people living with diabetes by 2020."
Since Novo Nordisk launched its first access to care strategy in 2001, diabetes has become a major global health challenge. There are now an estimated 387 million people worldwide with diabetes and the number is expected to rise to over half a billion by
20351.
The 2014 Access to Medicine Index highlighted two of the company's access to diabetes care initiatives - the http://www.changingdiabetesaccess.com/our-contributions/reaching-the-base-of-the-pyramid.aspBase of the Pyramidproject and the Changing Diabetes® in Childrenprogramme. The Base of the Pyramid project takes an integrated approach together with faith-based organisations to improve diagnosis, treatment and diabetes education for the working poor in developing countries. The Changing Diabetes® in Children programme provides medicine free of cost, treatment and patient education for children living with type 1 diabetes in low-income countries.
"We have the knowledge, capabilities and commitment to improve the health of people living with diabetes regardless of where they live," says Lars Rebien Sørensen. "As the
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Page 2 of 2
world leader in diabetes care, we will continue to work with governments, health
organisations and communities to make this a reality across the globe."
The ranking of the 2014 Access to Medicine Index is based on measurements of 21
pharmaceutical companies' policies and practices in improving access to medicine across
a specific range of countries, diseases and product types. The Access to Medicine Index is published every two years.
Read mo re a bout No v o No rd isk' s a ppro ac h to acc es s to d iab ete s care
View the full 2014 Access to Medicine Index
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately
41,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.
Further informationMedia:
Charlotte Zarp-Andersson +45 3079 7603 czpa@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@n o vo n+o4 r d5 is3k0 .7c o5 m3479
+m4rz5@3n0o7v5o3n
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 mailto:fdni@novonordisk.comfdni@novonordisk.com
1 IDF Diabetes Atlas 2014
Novo Nordisk A/SCorporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
|
distributed by
|
